Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.48 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.42 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.42 |
| ▸ | TK2 | O00142 | 2/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | UMPS | P11172 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26236136 | 1.00 | PYGM (0.48) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL30765011 | 0.90 | PYGM (0.44) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15798509 | 0.90 | PYGM (0.47) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL12245097 | 0.88 | PYGM (0.42) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL12667528 | 0.88 | PYGM (0.42) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL12223730 | 0.88 | PYGM (0.42) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15810684 | 0.88 | PYGM (0.44) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL30991676 | 0.88 | P2RY2 (0.53) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15798317 | 0.87 | PYGM (0.45) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15810644 | 0.87 | PYGM (0.45) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078356-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | claimed |
| US-12398379-B2 | Compositions and methods for treating ornithine transcarbamylase deficiency | ARCTURUS THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | claimed |
| US-20240002815-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS, INC. | 2024-01-04 | — | — | US | claimed |
| US-11685906-B2 | Compositions and methods for treating ornithine transcarbamylase deficiency | ARCTURUS THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | claimed |
| US-20260078356-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260069677-A1 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES | ARCTURUS THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260015641-A1 | METHODS FOR IN VITRO TRANSCRIPTION | ARCTURUS THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12509698-B2 | Synthesis and structure of high potency RNA therapeutics | ARCTURUS THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4658307-A2 | METHODS AND COMPOSITIONS FOR QUADRIVALENT INFLUENZA VACCINE | Arcturus Therapeutics, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12398379-B2 | Compositions and methods for treating ornithine transcarbamylase deficiency | ARCTURUS THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-12390524-B2 | Compositions and methods for inducing immune responses | ARCTURUS THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-3630964-B1 | THERAPEUTICS FOR GLYCOGEN STORAGE DISEASE TYPE III | ULTRAGENYX PHARMACEUTICAL INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20210290752-A1 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES | ARCTURUS THERAPEUTICS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20210290756-A1 | CORONAVIRUS VACCINE COMPOSITIONS AND METHODS | ARCTURUS THERAPEUTICS, INC. | 2021-09-23 | — | — | US | disclosed |
| WO-2021183564-A1 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES | ARCTURUS THERAPEUTICS, INC. (US) | 2021-09-16 | — | — | WO | disclosed |
| US-20210284974-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20200297634-A1 | METHOD OF MAKING LIPID-ENCAPSULATED RNA NANOPARTICLES | ARCTURUS THERAPEUTICS, INC. | 2020-09-24 | — | — | US | disclosed |
| EP-3630985-A1 | SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS | Arcturus Therapeutics, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018222890-A1 | SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS | ARCTURUS THERAPEUTICS, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| WO-2018160592-A1 | TRANSLATABLE MOLECULES AND SYNTHESIS THEREOF | ARCTURUS THERAPEUTICS, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290752-A1 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES | STING1, EIF2AK2, RNGTT | PYGM 2588/4885SLC28A1 3651/4885SLC28A2 3790/4885 |
| US-20210284974-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCY | OTC, OAT, ODC1 | PYGM 2585/4885SLC28A1 453/4885SLC28A2 456/4885 |
| US-20260015641-A1 | METHODS FOR IN VITRO TRANSCRIPTION | RNMT, RNGTT, POLM | PYGM 714/4885SLC28A1 200/4885SLC28A2 186/4885 |
| US-12390524-B2 | Compositions and methods for inducing immune responses | STING1, EIF2AK2, RNGTT | PYGM 2588/4885SLC28A1 3651/4885SLC28A2 3790/4885 |
| US-20200297634-A1 | METHOD OF MAKING LIPID-ENCAPSULATED RNA NANOPARTICLES | AUP1, RNGTT, LIPC | PYGM 4854/4885SLC28A1 2741/4885SLC28A2 3307/4885 |
| US-12509698-B2 | Synthesis and structure of high potency RNA therapeutics | IGF2BP3, SERPINC1, IGF2BP2 | PYGM 3892/4885SLC28A1 3845/4885SLC28A2 3161/4885 |
| US-20240002815-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | OTC, ODC1, OSGEP | PYGM 3238/4885SLC28A1 528/4885SLC28A2 465/4885 |
| US-20210290756-A1 | CORONAVIRUS VACCINE COMPOSITIONS AND METHODS | SARS1, RNGTT, STING1 | PYGM 2573/4885SLC28A1 4180/4885SLC28A2 4342/4885 |
| US-12398379-B2 | Compositions and methods for treating ornithine transcarbamylase deficiency | OTC, ODC1, OSGEP | PYGM 3238/4885SLC28A1 528/4885SLC28A2 465/4885 |
| US-11685906-B2 | Compositions and methods for treating ornithine transcarbamylase deficiency | OTC, ODC1, OSGEP | PYGM 3238/4885SLC28A1 528/4885SLC28A2 465/4885 |
| US-20260069677-A1 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES | STING1, MAVS, MYD88 | PYGM 2110/4885SLC28A1 568/4885SLC28A2 400/4885 |
| US-20260078356-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | OTC, OAT, POLRMT | PYGM 1852/4885SLC28A1 449/4885SLC28A2 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.